An investor asked on the investor interaction platform: Hello, as of January 2022, what drugs are currently being accepted for listing
Jiangsu Hengrui Medicine Co.Ltd(600276) (600276. SH) said on the investor interaction platform on January 20 that up to now, the company’s innovative drugs repagliptin, shr3680 tablets and shr8008 capsules are in the process of accepting the listing application.
